A powerful House committee has cleared two psychedelics research amendments and another measure on labeling pharmaceuticals with information about interactions with marijuana for floor consideration as part of large-scale spending bills.
On Saturday, the House Rules Committee advanced four appropriations bills with numerous proposed amendments, setting the stage for floor votes as a government funding deadline at the end of this month quickly approaches. Two of the spending bills could see drug policy reform measures attached.
The committee advanced two GOP-led amendments on psychedelics for a bill covering funding for the Department of Defense (DOD).
One, sponsored by Reps. Morgan Luttrell (R-TX) and Dan Crenshaw (R-TX), would provide $15 million in funding for DOD to carry out “Psychedelic Medical Clinical Trials.”
Another from Crenshaw would require the Defense Health Agency to “submit a report to Congress on options to ensure that active-duty service members who are suffering from Traumatic Brain Injuries (TBI) and Post-Traumatic Stress Disorder (PTSD) are able to participate in clinical trials under the Department of Veterans Affairs for the purposes of studying the effectiveness of psychedelic substances.”
The Rules Committee previously made the amendments in order, but broader disagreement among lawmakers over the appropriations bill prevented the
Read full article on Marijuana Moment
